Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease"
Eo. Meltzer, Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease", ANN ALLER A, 84(2), 2000, pp. 176
Objective: This review focuses on the shared pathophysiology of asthma and
allergic rhinitis. The similarities illustrate the "one linked airway disea
se" concept, a unifying theory of these upper and lower airway inflammatory
disorders. Since leukotrienes are mediators in both conditions, studies ha
ve been performed to assess the potential therapeutic role of cysteinyl leu
kotriene antagonists. The purpose of this paper is to provide an overview o
f the accumulating data concerning these agents in treating asthma and alle
rgic rhinitis.
Data Sources: Relevant publications obtained from a literature review.
Study Selection: Relevant publications on the topics of leukotrienes, leuko
triene receptor antagonists, asthma, and allergic rhinitis were critically
evaluated.
Results and Conclusions: Studies to date have documented the efficacy of cy
steinyl leukotriene receptor antagonists for asthma. The pathophysiology of
allergic rhinitis and its similarities to asthma suggest that these agents
could play a significant therapeutic role in managing this upper airway di
sorder. Because the leukotriene antagonists are oral agents, they may be va
luable in treating not only either condition but also both at the same time
when they coexist. They appear to be beneficial when prescribed as the ini
tial medicine and when used in conjunction with other therapies.